



## **VasoGenix and QLT to Develop Major New Treatment for Congestive Heart Failure**

[ PR Newswire · 2005-04-11 ]

LENEXA, Kan., April 11 /PRNewswire/ -- VasoGenix Pharmaceuticals, Inc., based in Lenexa, Kansas, announces that it has signed a worldwide agreement with QLT USA, Inc. to develop a sustained-release formulation of VasoGenix's Calcitonin Gene Related Peptide (CGRP) using QLT's Atrigel(R) biodegradable sustained release drug delivery system. Under the terms of the agreement VasoGenix has contracted with QLT to develop the delivery system for CGRP and VasoGenix has the option to acquire an exclusive worldwide royalty-bearing license. Commenting on the agreement, G. Lee Southard, Ph.D., Chairman and CEO of VasoGenix said, "In combining CGRP, a new and promising drug to treat cardiac conditions with the premier and proven properties of the Atrigel(R) system, we have the potential to provide a major new treatment for congestive heart failure, which is considered by many to be the most expensive disease in America at an estimated cost of \$38 billion per year. The release of CGRP from an Atrigel(R) depot promises to provide sustained regulation of important hemodynamic parameters essential to improving patient outcomes and significantly reduce the economic burden of the disease on the health care system."

VasoGenix Pharmaceuticals, Inc. is a privately held, early stage biotechnology and pharmaceutical development company focused on the research, development and commercialization of calcitonin gene related peptide (CGRP) as a new treatment for cardiovascular disease.

*Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward- looking statements by the use of words such as, "expects," "plans," "estimates," "projects," "promises," "intends," "believes," and similar expressions that do not relate to historical matters. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, the inability to identify investors, and/or strategic partners or, if identified, the inability to enter into an acceptable agreement with such investors and/or strategic partners. All forward-looking statements in this press release are made as of today, based upon information known to management as of the date hereof. VasoGenix assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.*

Atrigel(R) is a registered trademark of QLT USA, Inc.